000210401 001__ 210401
000210401 005__ 20240229154905.0
000210401 0247_ $$2doi$$a10.1007/s10198-022-01561-8
000210401 0247_ $$2pmid$$apmid:36656403
000210401 0247_ $$2ISSN$$a1618-7598
000210401 0247_ $$2ISSN$$a1439-3972
000210401 0247_ $$2ISSN$$a1439-6637
000210401 0247_ $$2ISSN$$a1618-7601
000210401 037__ $$aDKFZ-2023-00125
000210401 041__ $$aEnglish
000210401 082__ $$a610
000210401 1001_ $$00000-0001-9626-2934$$aNguyen, Hoa Thi$$b0
000210401 245__ $$aCost and cost-effectiveness of four different SARS-CoV-2 active surveillance strategies: evidence from a randomised control trial in Germany.
000210401 260__ $$aHeidelberg$$bSpringer$$c2023
000210401 3367_ $$2DRIVER$$aarticle
000210401 3367_ $$2DataCite$$aOutput Types/Journal article
000210401 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698219024_28570
000210401 3367_ $$2BibTeX$$aARTICLE
000210401 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000210401 3367_ $$00$$2EndNote$$aJournal Article
000210401 500__ $$a2023 Dec;24(9):1545-1559
000210401 520__ $$aThe COVID-19 pandemic has entered its third year and continues to affect most countries worldwide. Active surveillance, i.e. testing individuals irrespective of symptoms, presents a promising strategy to accurately measure the prevalence of SARS-CoV-2. We aimed to identify the most cost-effective active surveillance strategy for COVID-19 among the four strategies tested in a randomised control trial between 18th November 2020 and 23rd December 2020 in Germany. The four strategies included: (A1) direct testing of individuals; (A2) direct testing of households; (B1) testing conditioned on upstream COVID-19 symptom pre-screening of individuals; and (B2) testing conditioned on upstream COVID-19 symptom pre-screening of households.We adopted a health system perspective and followed an activity-based approach to costing. Resource consumption data were collected prospectively from a digital individual database, daily time records, key informant interviews and direct observations. Our cost-effectiveness analysis compared each strategy with the status quo and calculated the average cost-effective ratios (ACERs) for one primary outcome (sample tested) and three secondary outcomes (responder recruited, case detected and asymptomatic case detected).Our results showed that A2, with cost per sample tested at 52,89 EURO, had the lowest ACER for the primary outcome, closely followed by A1 (63,33 EURO). This estimate was much higher for both B1 (243,84 EURO) and B2 (181,06 EURO).A2 (direct testing at household level) proved to be the most cost-effective of the four evaluated strategies and should be considered as an option to strengthen the routine surveillance system in Germany and similar settings.
000210401 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000210401 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000210401 650_7 $$2Other$$aCOVID-19
000210401 650_7 $$2Other$$aCost
000210401 650_7 $$2Other$$aCost-effectiveness
000210401 650_7 $$2Other$$aGermany
000210401 650_7 $$2Other$$aSurveillance
000210401 7001_ $$aDenkinger, Claudia M$$b1
000210401 7001_ $$aBrenner, Stephan$$b2
000210401 7001_ $$aKoeppel, Lisa$$b3
000210401 7001_ $$aBrugnara, Lucia$$b4
000210401 7001_ $$aBurk, Robin$$b5
000210401 7001_ $$0P:(DE-He78)03ae15a30a7fa7191475148bf4e7f581$$aKnop, Michael$$b6$$udkfz
000210401 7001_ $$aBärnighausen, Till$$b7
000210401 7001_ $$aDeckert, Andreas$$b8
000210401 7001_ $$aDe Allegri, Manuela$$b9
000210401 773__ $$0PERI:(DE-600)2011428-X$$a10.1007/s10198-022-01561-8$$n9$$p1545-1559$$tThe European journal of health economics$$v24$$x1618-7598$$y2023
000210401 909CO $$ooai:inrepo02.dkfz.de:210401$$pVDB
000210401 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)03ae15a30a7fa7191475148bf4e7f581$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000210401 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000210401 9141_ $$y2023
000210401 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-12$$wger
000210401 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-12$$wger
000210401 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-12
000210401 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-26$$wger
000210401 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000210401 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000210401 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-08-26
000210401 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-08-26
000210401 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000210401 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J HEALTH ECON : 2022$$d2023-08-26
000210401 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000210401 9201_ $$0I:(DE-He78)A260-20160331$$kA260$$lA260 Zellmorphogenese und Signalübermittlung$$x0
000210401 980__ $$ajournal
000210401 980__ $$aVDB
000210401 980__ $$aI:(DE-He78)A260-20160331
000210401 980__ $$aUNRESTRICTED